Advanced search
Publication Cover
International Review of Psychiatry Volume 33, 2021 - Issue 3: New Therapeutic Advances in Mood Disorders; Guest Editors: Allan Young & Sameer Jauhar
Submit an article Journal homepage
5,205
Views
13
CrossRef citations to date
0
Altmetric
Review Articles

Ketamine for depression

Luke A. Jelena Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom;b South London and Maudsley NHS Foundation Trust, London, United KingdomCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6398-5239View further author information
ORCID Icon &
James M. Stonea Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom;b South London and Maudsley NHS Foundation Trust, London, United KingdomORCID Iconhttps://orcid.org/0000-0003-3051-0135View further author information
ORCID Icon
Pages 207-228 | Received 15 Jul 2020, Accepted 18 Nov 2020, Published online: 11 Feb 2021

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Evan Peskin, Jeffrey Gudin & Michael E Schatman. (2023) Increased Demand for Ketamine Infusions and Associated Complexities. Journal of Pain Research 16, pages 295-299.
Read now
Verônica Hühne, Carina Chacur, Marcos Vinícius Sousa de Oliveira, Pedro Pereira Fortes, Gabriela M. Bezerra de Menezes & Leonardo F. Fontenelle. (2023) Considerations for the treatment of obsessive-compulsive disorder in patients who have comorbid major depression. Expert Review of Neurotherapeutics 23:11, pages 955-967.
Read now

Articles from other publishers (11)

O. Damri, S. Natour, S. Asslih & G. Agam. (2023) Does treatment with autophagy-enhancers and/or ROS-scavengers alleviate behavioral and neurochemical consequences of low-dose rotenone-induced mild mitochondrial dysfunction in mice?. Molecular Psychiatry 28:4, pages 1667-1678.
Crossref
Jared VanderZwaag, Torin Halvorson, Kira Dolhan, Eva Šimončičová, Benneth Ben-Azu & Marie-Ève Tremblay. (2022) The Missing Piece? A Case for Microglia’s Prominent Role in the Therapeutic Action of Anesthetics, Ketamine, and Psychedelics. Neurochemical Research 48:4, pages 1129-1166.
Crossref
Aleksandra Gliwińska, Justyna Czubilińska-Łada, Gniewko Więckiewicz, Elżbieta Świętochowska, Andrzej Badeński, Marta Dworak & Maria Szczepańska. (2023) The Role of Brain-Derived Neurotrophic Factor (BDNF) in Diagnosis and Treatment of Epilepsy, Depression, Schizophrenia, Anorexia Nervosa and Alzheimer’s Disease as Highly Drug-Resistant Diseases: A Narrative Review. Brain Sciences 13:2, pages 163.
Crossref
Kai Zhang, Yitan Yao & Kenji Hashimoto. (2023) Ketamine and its metabolites: Potential as novel treatments for depression. Neuropharmacology 222, pages 109305.
Crossref
Susan Miller, Walter Moos, Barbara Munk, Stephen Munk, Charles Hart & David Spellmeyer. 2023. Managing the Drug Discovery Process. Managing the Drug Discovery Process 207 338 .
Giordano Novak Rossi, Lorena T. L. Guerra, Glen B. Baker, Serdar M. Dursun, José Carlos Bouso Saiz, Jaime E. C. Hallak & Rafael G. dos Santos. (2022) Molecular Pathways of the Therapeutic Effects of Ayahuasca, a Botanical Psychedelic and Potential Rapid-Acting Antidepressant. Biomolecules 12:11, pages 1618.
Crossref
Luke A. Jelen & Allan H. Young. (2022) New antidepressants: New day or false dawn?. European Neuropsychopharmacology 63, pages 1-3.
Crossref
Agnieszka Mechlińska, Adam Włodarczyk, Marta Gruchała-Niedoszytko, Sylwia Małgorzewicz & Wiesław Jerzy Cubała. (2022) Dietary Patterns of Treatment–Resistant Depression Patients. Nutrients 14:18, pages 3766.
Crossref
Robert Sotille, Herpreet Singh, Anne Weisman & Thomas Vida. (2022) Unraveling the Mysteries of Mental Illness With Psilocybin. Cureus.
Crossref
Yoosuk An, Seon Young Park & Ung Gu Kang. (2022) “Drugs of Abuse” as a “New Antidepressant”: - A Review on Pharmacological Mechanisms, Antidepressant Effects, and Abuse Potential. Journal of Korean Neuropsychiatric Association 61:4, pages 243.
Crossref
Felicia Ceban, Joshua D. Rosenblat, Kevin Kratiuk, Yena Lee, Nelson B. Rodrigues, Hartej Gill, Mehala Subramaniapillai, Flora Nasri, Leanna M. W. Lui, Orly Lipsitz, Anil Kumar, Jung Goo Lee, Edmond H. Chau, Bing Cao, Kangguang Lin, Roger C. Ho, Rodrigo B. Mansur, Jennifer Swainson & Roger S. McIntyre. (2021) Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders. CNS Drugs 35:9, pages 925-934.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.